Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
10 mai 2022 07h00 HE
|
Cogent Biosciences, Inc.
Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a portfolio of discovery stage programs, creating potential best-in-class...
Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
06 mai 2022 08h00 HE
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event
11 avr. 2022 07h00 HE
|
Cogent Biosciences, Inc.
New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors ...
Cogent Biosciences to Host Virtual R&D Investor Event
29 mars 2022 07h00 HE
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for...
Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results
15 mars 2022 07h00 HE
|
Cogent Biosciences, Inc.
APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients APEX initial clinical data presentation expected in the first half of 2022 R&D Investor Event planned for...
Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022
08 mars 2022 17h10 HE
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference
09 févr. 2022 07h00 HE
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates
11 mai 2020 16h30 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced...
Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates
26 mars 2020 07h30 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today...
Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital
20 mars 2020 07h30 HE
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today...